Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

INCLUSION CRITERIA: * 4 to 18 years of age, inclusive. The patient's cognitive ability must be considered by a parent or healthcare professional to be at least at a 4 year-old level. * Newly diagnosed (i.e., not relapsed) with any malignancy. * Patients are not required to be registered on a COG therapeutic trial. * The patient's current chemotherapy treatment plan must include at least 1 course of * cisplatin at ≥ 50 mg/m2/dose or * ifosfamide plus etoposide or doxorubicin or * cyclophosphamide plus an anthracycline. * Patients may have previously received other chemotherapy. * The patient's current treatment plan must include an anti-emetic regimen with either ondansetron or granisetron on a scheduled basis. Patients may also receive dexamethasone for antiemetic prophylaxis during the acute phase at the discretion of the treating physician. Patients ≥ 12 years old may also receive aprepitant in conjunction with dexamethasone for antiemetic prophylaxis at the discretion of the treating physician. * Patients needing anti-emetic treatment for breakthrough nausea/vomiting may also receive anti-emetic agents on an as needed (PRN) basis. * The patient (parent/guardian) must be English-speaking (i.e., able to read and speak in English) since the PeNAT has been validated only in English. * All patients and/or their parents or legal guardians must sign a written informed consent (patient assent is also recommended when applicable according to each institution's policy). EXC…